MedTrace Logo

Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements

NCT05858307 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-03-27

No results posted yet for this study

Summary

This study aims to assess the association of Anti-Müllerian hormone (AMH) with polycystic ovarian syndrome, premature ovarian insufficiency and fertility. The main objectives include the following:

1. To study the level of serum AMH in women with PCOS and to evaluate the utility of serum AMH in the diagnosis of PCOS.
2. To evaluate the level of serum AMH in women with POI and to evaluate the utility of serum AMH in the management of POI.
3. To evaluate the associations of basal AMH level with FSH level and AFC respectively for women undergoing ART treatment.
4. To determine the optimal regimen of gonadotropin for ovarian stimulation for women undergoing ART treatment.
5. To evaluate the predictive value of serum AMH in reproductive outcomes including oocyte quality, embryo quality, pregnancy loss, clinical pregnancy and live birth rate in women undergoing ART treatment.

Conditions

  • Anti-Müllerian Hormone
  • Polycystic Ovarian Syndrome
  • Premature Ovarian Insufficiency
  • Fertility Issues

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • PUI WAH JACQUELINE CHUNG · Chinese University of Hong Kong

Eligibility

Min Age
10 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-22
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05858307 on ClinicalTrials.gov